Company Search
CEO Interview
Drive With Dynacor Video Series
TSX_DNG on 2012-05-17 10:38Dynacor has released a new video series called the "Drive With Dynacor". http://youtu.be/seFbg2CXt6U
NAI Blog
My Top Junior Oil Stock in the Permian Basin “Tight” Oil Play Keith Schaefer on 2012-04-26 07:40:54Part 2: The Permian Basin – Cline Shale Resource Play
Company News - Company Data
Helix BioPharma Corp. Appoints Jack Kay as Chairman of the Board and Professor Kazimierz Roszkowski-Sliz as European Medical Director
Posted 2012-01-09 00:46NAI Editing
announces that Mr. Jack M. Kay has been appointed as Chairman of the Board. Mr. Kay replaces Dr. Donald H. Segal in this capacity. Dr.Helix BioPharma Corp. Announces Meeting of Shareholders
Posted 2011-11-07 02:21NAI Editing
announces that it has called its annual general meeting of shareholders (the "Meeting") for January 30, 2012, with a record date of December 2, 2011.Helix BioPharma Corp. Receives Shareholder Requisition to Hold Meeting to Elect Directors
Posted 2011-10-19 05:57NAI Editing
, today announced that the directors have received a shareholder requisition to call a meeting of shareholders to elect directors and set the number of directors to be elected at the meeting at seven Helix BioPharma Announces Private Placement for Net Proceeds of $2.0 Million
Posted 2011-03-31 07:43NAI Editing
,a developer of biopharmaceutical drug candidates for the prevention and treatment of cancer, today announced that it has completed a private placement transaction, issuing 918,365 units for net proceHelix BioPharma Announces $3.9 Million Private Placement
Posted 2011-03-28 08:32NAI Editing
,a developer of biopharmaceutical drug candidates for the prevention and treatment of cancer, today announced that it has received subscriptions for the purchase, by way of private placement, of 1,652Helix BioPharma Corp. Reports That a U.S. Patent Has Been Issued for the Lung Cancer-Specific Antibody Used in Its Drug Candidate L-DOS47
Posted 2011-03-02 11:46NAI Editing
, a developer of biopharmaceutical drug candidates for the prevention and treatment of cancer, today announced the issuance of a patent (U.S. Patent No.Helix BioPharma Corp. Files IND for a U.S. Phase I Clinical Study of Its Cancer Drug Candidate L-DOS47
Posted 2011-01-07 09:50NAI500 Admin
, a developer of biopharmaceutical drug candidates for the prevention and treatment of cancer, today announced that it has filed an investigational new drug ("IND") application with the United States Helix BioPharma Corp. Reports Positive Efficacy and Safety Findings From Phase II Study of Its Topical Interferon Alpha-2b in Patients With Low-Grade Cervical Lesions
Posted 2010-10-21 11:21NAI500 Admin
,a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced positive efficacy and safety findings from its recently completed Phase II pharmacokHelix BioPharma Corp. Retains CFSG1 as Its Exclusive U.S. Investor Relations Firm
Posted 2010-10-19 10:12NAI500 Admin
,a biopharmaceutical company focused on cancer therapy, today announced that it has retained Consulting for Strategic Growth 1 ("CFSG1") as its exclusive U.S. investor relations representative.Helix BioPharma Completes Definitive GLP Toxicology Studies With L-DOS47 and is Making Final Preparations for its Planned Phase I/II Clinical Study IND/CTA Submissions
Posted 2010-10-12 09:28NAI500 Admin
today announced that it has completed its definitive GLP, rodent and primate, repeat-dose toxicology studies with L-DOS47.
Posted 2012-01-09 00:46
NAI Editingannounces that Mr. Jack M. Kay has been appointed as Chairman of the Board. Mr. Kay replaces Dr. Donald H. Segal in this capacity. Dr.Helix BioPharma Corp. Announces Meeting of Shareholders
Posted 2011-11-07 02:21
NAI Editingannounces that it has called its annual general meeting of shareholders (the "Meeting") for January 30, 2012, with a record date of December 2, 2011.Helix BioPharma Corp. Receives Shareholder Requisition to Hold Meeting to Elect Directors
Posted 2011-10-19 05:57
NAI Editing, today announced that the directors have received a shareholder requisition to call a meeting of shareholders to elect directors and set the number of directors to be elected at the meeting at seven Helix BioPharma Announces Private Placement for Net Proceeds of $2.0 Million
Posted 2011-03-31 07:43
NAI Editing,a developer of biopharmaceutical drug candidates for the prevention and treatment of cancer, today announced that it has completed a private placement transaction, issuing 918,365 units for net proceHelix BioPharma Announces $3.9 Million Private Placement
Posted 2011-03-28 08:32
NAI Editing,a developer of biopharmaceutical drug candidates for the prevention and treatment of cancer, today announced that it has received subscriptions for the purchase, by way of private placement, of 1,652Helix BioPharma Corp. Reports That a U.S. Patent Has Been Issued for the Lung Cancer-Specific Antibody Used in Its Drug Candidate L-DOS47
Posted 2011-03-02 11:46
NAI Editing, a developer of biopharmaceutical drug candidates for the prevention and treatment of cancer, today announced the issuance of a patent (U.S. Patent No.Helix BioPharma Corp. Files IND for a U.S. Phase I Clinical Study of Its Cancer Drug Candidate L-DOS47
Posted 2011-01-07 09:50
NAI500 Admin, a developer of biopharmaceutical drug candidates for the prevention and treatment of cancer, today announced that it has filed an investigational new drug ("IND") application with the United States Helix BioPharma Corp. Reports Positive Efficacy and Safety Findings From Phase II Study of Its Topical Interferon Alpha-2b in Patients With Low-Grade Cervical Lesions
Posted 2010-10-21 11:21
NAI500 Admin,a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced positive efficacy and safety findings from its recently completed Phase II pharmacokHelix BioPharma Corp. Retains CFSG1 as Its Exclusive U.S. Investor Relations Firm
Posted 2010-10-19 10:12
NAI500 Admin,a biopharmaceutical company focused on cancer therapy, today announced that it has retained Consulting for Strategic Growth 1 ("CFSG1") as its exclusive U.S. investor relations representative.Helix BioPharma Completes Definitive GLP Toxicology Studies With L-DOS47 and is Making Final Preparations for its Planned Phase I/II Clinical Study IND/CTA Submissions
Posted 2010-10-12 09:28
NAI500 Admintoday announced that it has completed its definitive GLP, rodent and primate, repeat-dose toxicology studies with L-DOS47.